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Recent preclinical studies showed the potential of nico-
tinamide adenine dinucleotide (NAD+) precursors to in-
crease oxidative phosphorylation and improve metabolic
health, but human data are lacking. We hypothesize that
the nicotinic acid derivative acipimox, an NAD+ precursor,
would directly affect mitochondrial function independent
of reductions in nonesterified fatty acid (NEFA) concentra-
tions. In a multicenter randomized crossover trial, 21
patients with type 2 diabetes (age 57.7 6 1.1 years, BMI
33.4 6 0.8 kg/m2) received either placebo or acipimox
250 mg three times daily dosage for 2 weeks. Acipimox
treatment increased plasma NEFA levels (759 6 44 vs.
1,135697mmol/L forplacebovs.acipimox,P<0.01)owing
to a previously described rebound effect. As a result, skel-
etal muscle lipid content increased and insulin sensitivity
decreased. Despite the elevated plasma NEFA levels, ex
vivo mitochondrial respiration in skeletal muscle in-
creased. Subsequently, we showed that acipimox treat-
ment resulted in a robust elevation in expression of
nuclear-encoded mitochondrial gene sets and a mitonu-
clear protein imbalance, which may indicate activation of
the mitochondrial unfolded protein response. Further
studies in C2C12 myotubes confirmed a direct effect of
acipimox on NAD+ levels, mitonuclear protein imbalance,
and mitochondrial oxidative capacity. To the best of our
knowledge, this study is the first to demonstrate that
NAD+ boosters can also directly affect skeletalmusclemi-
tochondrial function in humans.
Acipimox is a nicotinic acid analog used to treat hyper-
lipidemia (1,2). Besides its effects on cholesterol and tri-
glyceride levels, acipimox treatment acutely decreases
plasma nonesterified fatty acid (NEFA) concentrations
by 46–57%, which may lower ectopic fat accumulation
in type 2 diabetes (T2D) (3,4) and thereby improve
whole-body insulin sensitivity (5). Furthermore, elevated
plasma NEFA concentrations have been shown to deteri-
orate mitochondrial function (6), and lowering plasma
NEFA levels may, therefore, restore mitochondrial func-
tion. The latter is important because several features of
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muscle mitochondrial function can be impaired in
patients with T2D and may be related to insulin sensitiv-
ity (7–9). Indeed, some studies showed sustained benefi-
cial effects of acipimox treatment on plasma NEFA and
insulin sensitivity (3,10). A major shortcoming of these
studies, however, is that the last dose of acipimox was
given on the morning of the test days, making it impos-
sible to separate sustained effects from the acute effect of
the last acipimox dose given. Indeed, even after treatment
with acipimox four times daily for several weeks, a re-
bound increase in plasma NEFA levels can be observed
(11). Next to this rebound effect, acipimox is known to
induce flushing in a large number of patients (12), which
will limit the clinical relevance of acipimox for the treat-
ment of insulin resistance and mitochondrial dysfunction
and an urge for the development of alternative treat-
ments to improve mitochondrial oxidative capacity. In
that respect, nicotinamide adenine dinucleotide (NAD+)
precursors, such as nicotinamide riboside (NR) (13,14)
or nicotinamide mononucleotide (NMN) (15), have been
reported to improve oxidative metabolism in animal mod-
els. NR or NMN supplementation in mice resulted in
elevated NAD+ levels, sirtuin 1 (SIRT1) activation, and
beneficial adaptation in mitochondrial gene expression
profiles (13,15). Longer-term NR or NMN supplementa-
tion in mice fed a high-fat diet additionally improved
mitochondrial function and metabolic health (13,15).
Furthermore, NR did not activate the GPR109A re-
ceptor, which is responsible for the flushing observed
with acipimox treatment (16).
So far, NR and NMN have not been tested for efficacy or
safety in human clinical trials or for effects on mitochon-
drial metabolism. However, besides the known effects of
acipimox on lipolysis, acipimox is also an NAD+ precursor.
Because both NR/NMN and acipimox are NAD+ precursors
and acipimox is already available for clinical use in humans,
we examined the potential for such NAD+ precursors in
improving mitochondrial function in humans. To this end,
in this proof-of-concept study, we treated T2D patients
with acipimox for 2 weeks and examined the sustained
effects on mitochondrial metabolism in detail. To rule
out the acute lipid-lowering effects of the last dose of
acipimox, patients underwent measurements after an over-
night fast, omitting acipimox in the morning.
We found that despite an anticipated rebound effect
on plasma NEFA levels, acipimox has pronounced
effects in vivo, ex vivo, and in cell culture experiments
on mitochondrial function comparable to the effects of
other NAD+ precursors, such as NR and NMM, as found
in animals. These results suggest a strong potential for
novel, safe NAD+ precursors to boost mitochondrial
function in humans.
RESEARCH DESIGN AND METHODS
In the present multicenter, randomized, double-blind,
placebo-controlled crossover trial, 21 patients with T2D
were included (10 from the Maastricht University Medical
Center and 11 from the German Diabetes Center in
Düsseldorf) (Fig. 1). All T2D patients were treated with
placebo (celluose mycrocrystal PH 102) and acipimox (250
mg three times daily) for 2 weeks each in random order.
Between interventions, a 4-week washout period was
maintained. During both 2-week intervention periods,
patients were asked to stop their oral glucose-lowering
medication. At the end of both 2-week periods, patients
were provided with a standardized meal the day before
the clamp test. Patients were also advised to refrain from
physical exercise 3 days before the test days. After 2 weeks
of acipimox and placebo treatment, measurements were
performed to assess mitochondrial function, ectopic lipid
accumulation, and insulin sensitivity.
Subjects
Both male and postmenopausal female humans were
included (Table 1). Before inclusion in the study, partic-
ipants underwent physical examination and anthropome-
try measurements and completed a medical history
questionnaire, including a history of cardiovascular, renal,
and pulmonary disease; cancer; and duration of diabetes.
Additionally, routine medical laboratory tests, including
hematology, and a maximal aerobic capacity test with
concurrent electrocardiogram were performed as previ-
ously described (17). Body composition was determined
using hydrostatic weighing in Maastricht according to
Figure 1—Study design flowchart. After screening and subject characterization, patients were randomly assigned to either 2 weeks of
acipimox treatment or 2 weeks of placebo treatment. At the end of both treatments, mitochondrial function, ectopic lipid accumulation, and
insulin sensitivity were assessed. After a washout period of 4 weeks, patients entered in the other intervention arm such that all patients
served as their own control.
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the method of Siri (18). In Düsseldorf, body composition
was measured with DEXA scan. T2D patients had well-
controlled diabetes (HbA1c 7.08 6 0.16% [54 6 1.51
mmol/mol]) and were either on monotherapy with met-
formin (n = 16), on metformin combined with sulfonyl-
urea (n = 4), or on diet only (n = 1). Patients were allowed
to take other medications, such as the statins rosuvastin
(n = 2), atorvastatin (n = 1), and simvastatin (n = 1), and
antihypertensive (n = 10) and uricostatic (n = 6) drugs.
Other medications used included omeprazole, acetylsali-
cylic acid, antimigraine medication, and antidepressant
drugs (Supplementary Table 1).
Patients with a diagnosis of T2D for at least 1 year
were included. None of the participants were following
a weight loss dietary program, and all patients had
stable body weight for the last 6 months before the
study. The Maastricht University Medical Ethics Com-
mittee (the Netherlands) and the Medical Association
North Rhine in Düsseldorf (Germany) approved the
study, and written informed consent was obtained
from all participants before screening. The study was
performed according to the principles expressed in the
Declaration of Helsinki.
Hyperinsulinemic-Euglycemic Clamp
All participants underwent a two-step 6-h hyperinsulinemic-
euglycemic clamp (10 and 40 mU/m2/min) (19). After an
overnight fast, participants received a primed continuous
infusion of [6,6-2H2] glucose (0.04 mg/kg/min) to
determine rates of endogenous glucose production
(EGP) and whole-body glucose disposal (WGD) rates as
previously described (20). After 180 min, a low-insulin
infusion was started (10 mU/m2/min) with the coinfusion
of 0.1 mg/kg/min of somatostatin (21) for 3.5 h until
a steady state was reached, after which time blood sam-
pling and indirect calorimetry was performed for 30 min.
Thereafter, a high-insulin infusion was started (40
mU/m2/min) with the coinfusion of 0.1 mg/kg/min somato-
statin for 1.5 h, after which steady state was reached and
blood sampling and indirect calorimetry repeated. During
the clamp, oxygen consumption and carbon dioxide pro-
duction were measured with an automated respiratory gas
analyzer (calibrated daily) using a ventilated hood system
(Omnical; IDEE, Maastricht, the Netherlands). Whole-
body glucose and fat oxidation rates were calculated using
stoichiometric equations based on measured oxygen con-
sumption and carbon dioxide concentrations (22) with
the assumption that protein oxidation was negligible.
Muscle Biopsies and Analysis
Muscle biopsy specimens were taken from the m. vastus
lateralis before the clamp study under local anesthesia
(2% lidocaine) using the Bergström technique (23). Any
visible nonmuscle material was dissected from muscle
tissue. One portion was immediately frozen in liquid
nitrogen for biochemical analyses, one portion was fro-
zen in nitrogen-cooled isopentane and embedded in
Tissue-Tek for immunohistochemical analyses, and both
samples were stored at 280°C until further use. The re-
maining muscle tissue was used for mitochondrial respira-
tion analysis.
In the muscle tissue obtained, lipid accumulation was
assessed histochemically in cross sections using a modified
oil red O staining for fluorescence microscopy (24). In
addition, ;30 mg of the muscle tissue was used for
high-resolution respirometry to determine ex vivo mito-
chondrial function. ATP content was measured in muscle
tissue as described (14,25). Furthermore, immunoblotting
was used to detect protein levels of mitochondrial-
encoded cytochrome C oxidase I (MTCO1); succinate de-
hydrogenase complex, subunit A (SDHA); and heat shock
protein 60 (HSP60) (14,25). MTCO1 and SDHA anti-
bodies were from Abcam, and HSP60 antibody was
from Santa Cruz Inc. Coomassie staining of proteins was
used as a loading control and performed using a standard
protocol.
Mitochondrial Respiration in Permeabilized Muscle
Fibers
A small portion of the muscle biopsy sample (;30 mg)
was immediately placed in ice-cold biopsy preservation
medium (BIOPS; OROBOROS Instruments, Innsbruck,
Austria). Muscle fibers were permeabilized with saponin
as previously described (7). After completion of the per-
meabilization protocol, muscle fibers were transferred
into ice-cold mitochondrial respiration buffer (MiR05;




Age (years) 57.7 6 1.1
Weight (kg) 100.5 6 2.9
BMI (kg/m2) 33.4 6 0.8
Fat mass (%) 35.1 6 1.2
VO2max (mL/min/kg) 24.0 6 1.2
Systolic BP (mmHg) 149 6 2.6
Diastolic BP (mmHg) 92.8 6 1.9
FPG (mmol/L) 7.4 6 0.2
HbA1c (%) 7.1 6 0.2
HbA1c (mmol/mol) 54.0 6 1.5
AST (units/L) 23.7 6 1.7
ALT (units/L) 35.9 6 3.2
y-GT (units/L) 41.6 6 3.5
Total cholesterol (mmol/L) 8.4 6 3.5
HDL cholesterol (mmol/L) 1.2 6 0.1
LDL cholesterol (mmol/L) 2.6 6 0.2
Triglycerides (mmol/L) 2.0 6 0.2
NEFA (mmol/L) 672 6 70
Data are mean 6 SE unless otherwise indicated. ALT, alanine ami-
notransferase; AST, aspartate aminotransferase; BP, blood pres-
sure; FPG, fasting plasma glucose; y-GT, g-glutamyl transferase.
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function ex vivo was determined by measuring oxygen
consumption polarographically using a two-chamber Oxy-
graph (OROBOROS Instruments). Oxygen consumption,
or oxygen flux, reflects the first derivative of the oxygen
concentration (nmol/mL) in the respiration chambers
(pmol/s/mg) corrected for muscle tissue wet weight (2–
5 mg). To evaluate mitochondrial oxidative capacity, dif-
ferent substrate protocols were applied. In every protocol,
4.0 mmol/L malate was added to obtain state 2 respira-
tion followed by the addition of 8.0 mmol/L glutamate as
a substrate for complex I, which was combined with or
without 40.0 mmol/L palmitoylcarnitine. In addition, an
excess of 1.6 mmol/L ADP was added to evaluate state 3
respiration of complex I. (State 3 respiration reflects sub-
strate oxidation coupled to energy production.) Then, 8.0
mmol/L succinate was added to obtain state 3 respiration
of complex I and II. Finally, titrations (in steps of 0.5 mL
of 1.0 mmol/L) of the chemical uncoupler fluoro carbonyl
cyanide phenylhydrazone (FCCP) were added to evaluate
maximal respiratory capacity state U.
Measures of Mitochondrial Density
Mitochondrial DNA (mtDNA) copy number was deter-
mined as a marker for mitochondrial density using
quantitative real-time PCR based on the TaqMan probe
method. mtDNA copy number was calculated from the
ratio of NADH dehydrogenase subunit 1 to lipoprotein
lipase (mtDNA/nuclear DNA [nDNA]) as previously de-
scribed (7).
Plasma Assays
Blood collected in tubes containing EDTA was immedi-
ately centrifuged, and the plasma was stored at 280°C
until assayed. Plasma NEFA and glucose concentrations
were measured with enzymatic assays on Cobas Bio Fara
and Mira analyzers (NEFA: Wako NEFA-C test kit [Wako
Chemicals, Neuss, Germany]; glucose: hexokinase method
[Roche, Basel, Switzerland]). Insulin concentration was
determined by radioimmunoassay (Linco Research, St.
Charles, MO). Cholesterol, LDL, and triglyceride levels
were measured colorimetrically (Roche, Vienna, Austria).
RNA Analysis
Total RNA was isolated from human vastus lateralis
muscle biopsy specimens using the acidic guanidinium
thiocyanate method, purified with the RNeasy RNA
isolation kit (QIAGEN), and prepared simultaneously for
array analysis with all RNA integrity numbers $8.0.
Microarrays were analyzed using the Human Gene 2.0
ST platform (Affymetrix). Gene Set Enrichment Analysis
(GSEA) (Broad Institute) was performed using ontology
sets designed by the Reactome consortium (26). These
general gene sets were supplemented with specific custom
NAD+ booster gene sets designed and detailed in previous
studies (13,14,27,28).
In Vitro Cell Culture Study
C2C12 myoblasts were differentiated into myotubes as
described (29) in 6-well plates. Four-day–differentiated
myotubes were treated with acipimox 10 mol/L in normal
glucose (4.5 g/L) DMEM containing 1% albumin-bound
oleic acid (Sigma), 10% FCS, 2% HEPES, 1% nonessential
amino acids, and 1% penstrep. NAD+ was extracted 3 h
after the acipimox incubation and measured using high-
performance liquid chromatography as described (30).
Western blot analysis was performed 24 h after the
acipimox incubation. Mitochondrial respiration was mea-
sured 24 h after the acipimox incubation using high-
resolution respirometry as aforementioned (OROBOROS
Instruments). Respirometry was corrected for cell count
and viability of the cells loaded.
Calculations
Determination of atom percent enrichment of 2H was
done as previously described (31) after deproteinization.
Steele single-pool non–steady-state equations were used
to calculate WGD and EGP (32). Volume of distribution
was assumed to be 0.160 L/kg for glucose. Nonoxidative
glucose disposal (NOGD) was calculated as WGD 2
carbohydrate oxidation.
Statistics
Data are reported as mean 6 SE. Statistical analyses were
performed using SPSS version 16.0.2 for MacOSX (IBM
Corporation, Chicago, IL). Differences between the inter-
ventions were analyzed with a two-tailed paired Student t
test. Statistical significance was set a priori at P , 0.05.
RESULTS
Effect of Acipimox on Plasma Metabolite
Concentrations
Patients were treated with acipimox or placebo for 2
weeks. To test compliance with and efficacy of the
treatment, we determined plasma cholesterol and tri-
glyceride levels. Despite the short duration of the in-
tervention, cholesterol and triglyceride levels tended to
decrease upon acipimox treatment compared with pla-
cebo, indicating that administration of acipimox was
effective in the present patients (total cholesterol 5.6 6
0.3 vs. 5.1 6 0.3 mmol/L [P = 0.08], TG 2.6 6 0.4 vs.
1.7 6 0.3 mmol/L [P = 0.08], for placebo vs. acipimox).
We next determined the effect of acipimox treatment on
plasma NEFA levels, which we observed to increase rather
than decrease upon acipimox treatment, consistent with
the previously described rebound effect of acipimox
(11,33). Fasting plasma NEFA concentrations increased
from 0.77 6 0.05 mmol/L with placebo to 1.13 6 0.10
mmol/L with acipimox (P , 0.01) (Fig. 2A). Of note,
plasma NEFA levels remained significantly elevated
throughout the insulin-stimulated period of the hyperin-
sulinemic clamp (Fig. 2A).
Insulin Sensitivity
Acipimox has been suggested to improve insulin sensitiv-
ity; however, elevations of plasma NEFA levels are
generally associated with an induction of insulin re-
sistance (34). Therefore, we examined whether sustained
acipimox treatment influenced insulin sensitivity when
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the acute effect of acipimox was omitted. In noninsulin-
stimulated condition and at low insulin concentrations,
we observed no significant differences in insulin sensitivity
and metabolic flexibility between the acipimox- and placebo-
treated T2D patients. However, consistent with elevated
plasma NEFA levels, at high insulin concentrations (40
mU/m2/min), WGD and NOGD were lower upon acipimox
treatment (WGD 20.0 6 2.6 vs. 13.5 6 2.1 [P = 0.03] and
NOGD 9.9 6 2.6 vs. 2.5 6 3.1 mmol/kg/min [P = 0.02] for
placebo vs. acipimox) (Fig. 2B), whereas insulin-stimulated
oxidative glucose disposal was not affected (Fig. 2B). Addi-
tionally, EGP was less suppressed by insulin upon acipimox
treatment (1.7 6 0.8 vs. 3.4 6 0.5 mmol/kg/min for
placebo vs. acipimox, P = 0.05) (Fig. 2C).
The effect of high NEFA levels on insulin sensitivity
has been previously ascribed to fat accumulation in
skeletal muscle (34). Therefore, we examined the effect
of acipimox treatment on skeletal muscle lipid content
and found that intramyocellular lipid content was in-
creased from 2.8 6 0.5 to 3.8 6 0.8% of total fiber
area upon acipimox treatment (P , 0.05) (Fig. 2D).
Mitochondrial Capacity
Although acipimox induced a rebound increase of plasma
NEFA levels, which was associated with the development
of insulin resistance, we hypothesized that acipimox may
have a direct effect on mitochondrial oxidative capacity
independent of its confounding effects on NEFA levels.
Therefore, we first examined whether 2 weeks of acipimox
treatment resulted in increases in mitochondrial content.
mtDNA copy number was unaffected by acipimox
treatment (2,305 6 218 vs. 2,353 6 202 arbitrary units
for placebo vs. acipimox, P = 0.84). To investigate func-
tional improvements in mitochondrial respiration, we
next performed high-resolution respirometry in perme-
abilized muscle fibers. Ex vivo mitochondrial respiration
increased upon acipimox treatment for both state 3 and
maximal uncoupled respiration on malate/glutamate/suc-
cinate (Fig. 3A). Upon the addition of octanoylcarnitine,
only maximal uncoupled respiration was significantly
higher in the acipimox-treated condition (Fig. 3B). Be-
cause mtDNA content was not different between the
interventions, a similar tendency with increased mito-
chondrial respiration upon acipimox treatment was ob-
served after normalization for mitochondrial respiration
to mtDNA content (data not shown).
To find further evidence for a direct effect of acipimox
on mitochondrial metabolism, we performed microarray
analysis on vastus lateralis muscle biopsy specimens of
a small and randomly chosen subset of patients (n = 3).
Unbiased GSEA showed a robust and significant enrich-
ment for energy metabolism in acipimox-treated patients.
In particular, acipimox treatment resulted in a highly sig-
nificant enrichment of genes involved in the tricarboxylic
acid (TCA) cycle and electron transport chain (ETC), sug-
gesting a specific effect of acipimox on mitochondrial me-
tabolism (Fig. 4A). In fact, of all predefined gene sets, only
those directly related to mitochondrial metabolism were
significantly enriched (familywise error rate, P , 0.05).
However, no predefined gene sets specifically address
NAD+ metabolism, so we examined a custom-designed
gene set comprising genes known to be induced upon
Figure 2—Metabolic effects of 2 weeks of acipimox treatment or placebo in T2D patients. A: Effect of acipimox treatment for 2 weeks on
plasma NEFA concentrations in T2D patients, both in the fasted state as during a hyperinsulinemic-euglycemic clamp. Dashed and solid
arrows indicate the start of low (10 mU/m2/min) and high (40 mU/m2/min) infusion of insulin, respectively. B: WGD rates divided into
oxidative glucose disposal and NOGD. C and D: EGP and skeletal muscle lipid content as measured by ORO staining in the vastus lateralis
muscle. *P < 0.05. FFA, free fatty acid; ORO, oil red O.
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treatment with other compounds that boost cellular
NAD+ content, such as NR (13,14) and Poly (ADP-ribose)
polymerase (PARP) inhibitors (13,14,27,28). This custom
gene set was highly enriched in the acipimox-treated
patients, with particular similarity to gene sets targeted
by PARP inhibitors or other NAD+ precursors (Fig. 4B).
Furthermore, ATP content was markedly increased in the
acipimox-treated patients (35.2 6 21.3 vs. 70.0 6 24.5
relative light units/mg protein for placebo vs. acipimox,
P , 0.01) (Fig. 4C).
Recently, it has been hypothesized that part of the
beneficial effects of NAD+ boosting on mitochondrial me-
tabolism may involve the presence of a stoichiometric
imbalance between mitochondrial proteins encoded by
Figure 3—Two weeks of acipimox treatment improves mitochondrial respiration. Effect of acipimox treatment for 2 weeks on ex vivo
mitochondrial function measured in permeabilized fibers upon addition of complex I and II substrates without (A) and with (B) addition of
octanoylcarnitine as a substrate. Data are uncorrected for mtDNA. *P < 0.05. 3, state 3 after addition of ADP; CytC, cytochrome C; G,
glutamate; M, malate; O, octanoylcarnitine; S, succinate.
Figure 4—NAD+ signature after 2 weeks of acipimox treatment. A: GSEA of muscle biopsy specimens from humans before and after 2
weeks of acipimox treatment. In the Reactome gene set list, only one set is significantly changed between cohorts: TCA cycle and ETC,
which is upregulated in treated samples. B: We added a custom-designed gene set more directly related to NAD+ metabolism. The NAD+
booster gene set is significantly enriched in treated samples. C: ATP content measured by CellTiter-Glo chemiluminescence kit in muscle
biopsy specimens, corrected for protein loading, of placebo- and acipimox-treated T2D patients. **P < 0.01. D: Protein levels of mtDNA-
encoded MTCO1 and nDNA-encoded SDHA show a significant mitonuclear imbalance, leading to the induction of UPRmt, as reflected by
the induction of HSP60 expression in muscle biopsy specimens of T2D patients after placebo or acipimox treatment. Coomassie blue
staining served as a loading control. FWER, familywise error rate; ns, not significant; PARPi, PARP inhibitor; RLU, relative light unit.
1198 Acipimox on Muscle Mitochondrial Function Diabetes Volume 64, April 2015
the mtDNA and nDNA (i.e., a mitonuclear protein imbal-
ance) (25). This imbalance will lead to the induction of the
mitochondrial unfolded protein response (UPRmt), an
adaptive and hermetic signaling pathway that ultimately
repairs and improves mitochondrial function and meta-
bolic health in animal models ranging from the nematode
Caenorhabditis elegans to the mouse (14,25,35). In a subset
of subjects, we examined the presence of mitonuclear pro-
tein imbalance and UPRmt. Acipimox treatment tended to
increase the ratio of MTCO1 (an mtDNA-encoded ETC
protein) and SDHA (an nDNA–encoded ETC component)
protein content (MTCO1/SDHA 0.26 6 0.19 vs. 0.75 6
0.30 for placebo vs. acipimox treatment, P = 0.07) and
increased protein content of the mitochondrial chaperone
HSP60, which is induced during UPRmt (0.54 6 0.36 vs.
1.14 6 0.15 for placebo vs. acipimox, P , 0.05) (Fig. 4D).
To further investigate whether acipimox has a direct ef-
fect on muscle mitonuclear protein imbalance, we used
differentiated C2C12 cells incubated with acipimox or
an empty vehicle. First, we confirmed that acipimox is
able to increase NAD+ levels in muscle cells (Fig. 5A).
Next, 24-h incubation of C2C12 cells with 10 mmol/L
acipimox increased HSP60 (Fig. 5B) and the MTCO1/SDHA
ratio (Fig. 5C). Finally, to evaluate functional effects of
acipimox in C2C12 cells, we performed mitochondrial res-
piration assays in these cells 24 h after acipimox 10 mmol/L
acipimox incubation. FCCP-driven maximal state U respira-
tion was increased upon acipimox, mimicking the results
observed in the muscle biopsy specimens obtained from
the T2D participants (Fig. 5D). Together, the data ob-
tained in C2C12 cells strengthen the concept that acipimox,
as an NAD+ precursor, has direct effects on skeletal muscle
mitochondrial respiration and metabolism independent of
plasma NEFA levels.
DISCUSSION
We showed that treatment for 2 weeks with a standard
clinical dosage of acipimox, an NAD+ precursor, caused
a rebound effect in plasma NEFA concentrations when
measured after omission of the morning dose of acipimox
following overnight fasting, which was paralleled by re-
duced insulin sensitivity. Despite this rebound effect,
acipimox still improved mitochondrial oxidative capacity
and specifically activated a set of mitochondrial genes that
overlaps with the gene sets induced by NAD+ boosters,
such as NR, NMN, and PARP inhibitors (13–15,27,35), in
animal studies. These changes were accompanied by a sig-
nificant mitonuclear protein imbalance and the activation
of the UPRmt in human muscle biopsy specimens and in
cultured myotubes. To the best of our knowledge, this
study is the first to demonstrate that as in animals treated
with NAD+ boosters (14,35), UPRmt is present in humans.
These data hence show that NAD+ precursors activate
mitochondrial metabolism in humans using similar signal-
ing pathways as elucidated in a variety of model organ-
isms from worms to mice. Furthermore, the present data
urge testing of new NAD+ precursors in human clinical
trials that are devoid of the side effects observed after
sustained acipimox treatment, such as flushing and a re-
bound rise in NEFA levels.
The observation of elevated NEFA levels and impaired
insulin action contrasts some other studies that showed
a long-term reduction of plasma NEFA concentrations by
acipimox (3,10). Two major differences exist between
these studies and the present study. First, we adminis-
tered acipimox three times a day (i.e., after every meal)
according to clinical and medicinal guidelines, whereas
other studies used a dosage of four times a day. Second,
in all the previous studies, the last dose of acipimox was
given on the test day just before blood sampling and
experimental testing, which may obscure the sustained
effects of acipimox and result in acute effects of a morning
dose. Of note, it has been shown that acipimox treatment
can lead to a rebound effect, with plasma NEFA rising in
the morning, even with a dosage of four times a day (11).
Figure 5—Effect of acipimox on mitochondrial function in C2C12
cells. A: NAD+ levels after 3 h of acipimox 10 mmol/L incubation in
myotubes (n = 6). B: Evaluation of ATP5A, Uqcrc2, MTCO1, SDHA,
and HSP60 protein levels in C2C12 cells 24 h after acipimox 10
mmol/L incubation. HSP90 and Ponceau staining served as a load-
ing control. C: MTCO1/SDHA ratio after acipimox 10 mmol/L in-
cubation. D: Evaluation of mitochondrial respiration at the basal
condition or after oligomycin and FCCP administration in C2C12
cells 24 h after acipimox 10 mmol/L incubation (n = 6). *P < 0.05,
**P < 0.01. Oligom, oligomycin; Veh, vehicle.
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Thus, it was shown that the administration of acipimox
resulted in a sustained daytime rise in plasma NEFA, but
did not change plasma NEFA concentrations over a 24-h
period (11). This compensatory free fatty acid rise may be
necessary to maintain energy production, which is inter-
esting because mainly nocturnal concentrations of plasma
NEFAs are elevated in T2D patients (36), with insulin
resistance being more pronounced in the morning than
in the afternoon (37,38). Hence, the increase in plasma
NEFA concentrations upon acipimox is most likely a re-
flection of a nocturnal rebound effect, which was more
pronounced in the present study because we did not ad-
minister acipimox in the morning of the experimental test
days. Thus, it is likely that previous reports on the effect
of acipimox on plasma NEFA concentrations and insulin
sensitivity actually reflect the remnant effect of the last
dose taken rather than the prolonged treatment. Of note,
the reduction in insulin sensitivity upon acipimox treat-
ment in the present study was completely accounted for
by a reduction in insulin-stimulated NOGD, whereas
insulin-stimulated glucose oxidation was not affected by
the elevated plasma NEFA levels with acipimox treatment,
suggesting that acipimox prevented the decline in oxida-
tive capacity normally observed with high NEFA levels.
In that respect, the rebound rise in plasma NEFA
provides a model to study the direct effects of acipimox
on mitochondrial function, independent of reduced
plasma NEFA levels. We and others have previously
shown that acute elevation of plasma NEFA may actually
decrease mitochondrial biogenesis and function (21,39,40).
In concert with a direct effect of the NAD+ precursor
acipimox on mitochondrial function, we observed that in
humans, acipimox increased ex vivo mitochondrial oxida-
tive capacity and ATP production despite the potential
deleterious elevated plasma NEFA concentrations. A direct
effect of acipimox on muscle mitochondrial oxidative ca-
pacity and ATP production was confirmed in C2C12 myo-
tubes. Acipimox is a nicotinic acid analog and, thereby,
can increase intracellular NAD+ concentrations in skeletal
muscle. Reports have shown that stimulation of the NAD+
biosynthesis pathway through NR or NMN has beneficial
effects on mitochondrial function (13,15,35). Indeed, in
C2C12 myotubes, acipimox had a direct effect on enhanc-
ing NAD+ levels. Using an unbiased microarray approach,
we also observed that acipimox had clear and significant
effects on mitochondrial gene expression in skeletal muscle
biopsy specimens from T2D participants. Most striking was
the observation that acipimox induced a gene expression
signature that was similar to that we observed previously
when animals were treated long term with the NAD+
boosters, such as NR (13) and PARP inhibitors (27,35).
Furthermore, we show that 2 weeks of acipimox treatment
induced a mitonuclear protein imbalance both in cell cul-
ture and in ex vivo analysis, which is indicative of an acti-
vation of the UPRmt, a pathway that we recently showed to
be involved in mediating the beneficial effects of NAD+ on
metabolic health (14).
Taken together, the present results show for the first
time in humans that an NAD+ precursor like acipimox
activates mitochondrial metabolism in human skeletal
muscle and induces a mitonuclear protein imbalance
and UPRmt. This beneficial impact of acipimox on mito-
chondrial metabolism is all the more striking because it
occurs despite the negative effects of acipimox on plasma
NEFA levels and insulin sensitivity. These findings sug-
gest that although acipimox itself may not be a suitable
candidate, new NAD+ precursors devoid of such side
effects, such as NR and NMN, may potentially act as
mitochondrial boosters. Human clinical trials with such
agents are urgently needed given that interventions tar-
geting mitochondrial function, such as caloric restriction
(41), exercise (42), and resveratrol (43), have been shown
to be effective in improving metabolic health.
In conclusion, a 2-week intervention with clinical dosages
of acipimox led to a rebound rise in plasma NEFA con-
centration, which negatively affected insulin sensitivity.
Regardless of this negative effect, skeletal muscle mitochon-
drial oxidative capacity and ATP production improved, most
likely through alterations in NAD+ levels and activation of
mitochondrial metabolism and the UPRmt. Future research
is needed to investigate the safety and efficacy of NAD+
precursors to boost mitochondrial function and improve
metabolic health in human subjects, such as T2D patients.
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